Summary of clinical results
DUCRAY
Tolerance and efficacy of DEXYANE anti-scratching emollient balm
Tolerance and efficacy of DEXYANE anti-scratching emollient balm in patients with mild to moderate atopic eczema, under dermatological and pediatric control
Population
53 subjects (21 adults, 17 children, 15 infants) with mild to moderate atopic eczema (SCORAD between 10 and 25)
Application of DEXYANE anti-scratching emollient balm
Application once a day for 3 weeks, to the face and body
Usual cleansing product
Evaluation criteria
- Evolution of the severity of atopic eczema via the SCORAD questionnaire (Scoring atopic dermatitis)
- Scoring of the intensity of xerosis (4-point scale; 0 = absent to 4 very severe) and pruritus (VAS)
- Evaluation of sleep quality (VAS)
- Evaluation of the impact of eczema on children's quality of life (CDLQI)
- Skin tolerance under dermatological and pediatric control
Results
- Significant decrease in SCORAD of -50% after 1 week of application and -69% after 3 weeks (p<0.05).
- Significant decrease in pruritus intensity of -69% after 3 weeks of application (p<0.05).
- Significant decrease in the intensity of xerosis of -81% after 3 weeks of application (p<0.05).
- Significant decrease in insomnia of -91% (p<0.05) at 3 weeks.
- Significant decrease in the impact of eczema on children's quality of life of -89% at 3 weeks (p<0.05).
- Very good skin tolerance.
Conclusion
- Reduction of xerosis and pruritus associated with atopic eczema
- Improved quality of life and sleep
- Very good skin tolerance
More summaries of clinical results
Want to read on?
This access is reserved for professionals, registered on Pierre Fabre For Med.
To access the full content, please register or log in if you already have an account.